Tetrakis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acteylcholine Receptors by Crooks, Peter A. et al.
University of Kentucky
UKnowledge
Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences
1-14-2014
Tetrakis-Quaternary Ammonium Salts and
Methods for Modulating Neuronal Nicotinic
Acteylcholine Receptors
Peter A. Crooks
University of Kentucky, pcrooks@uky.edu
Linda P. Dwoskin
University of Kentucky, ldwoskin@email.uky.edu
Zhnefa Zhang
University of Kentucky, zhangzhenfa@uky.edu
Marharyta Pivavarchyk
University of Kentucky
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in
Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Crooks, Peter A.; Dwoskin, Linda P.; Zhang, Zhnefa; and Pivavarchyk, Marharyta, "Tetrakis-Quaternary Ammonium Salts and
Methods for Modulating Neuronal Nicotinic Acteylcholine Receptors" (2014). Pharmaceutical Sciences Faculty Patents. 18.
https://uknowledge.uky.edu/ps_patents/18
(12) United States Patent 
Crooks et al. 
US008629163B2 
US 8,629,163 B2 
Jan. 14, 2014 
(10) Patent N0.: 
(45) Date of Patent: 
(54) TETRAKIS-QUATERNARYAMMONIUM 
SALTS AND METHODS FOR MODULATING 
NEURONAL NICOTINIC ACTEYLCHOLINE 
RECEPTORS 
(75) Inventors: Peter A. Crooks, Nicholasville, KY 
(US); Linda P. DWoskin, Lexington, KY 
(US); Zhenfa Zhang, Lexington, KY 
(US); Marharyta Pivavarchyk, 
Lexington, KY (U S) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (U S) 
( * ) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
USC 154(b) by 72 days. 
(21) Appl.No.: 12/260,502 
(22) Filed: Oct. 29, 2008 
(65) Prior Publication Data 
US 2009/0143424 A1 Jun. 4, 2009 
Related US. Application Data 
(60) Provisional application No. 61/001,196, ?led on Oct. 
(52) US. Cl. 
USPC ......... .. 514/332; 514/333; 514/359; 546/186; 
548/ 518 
(58) Field of Classi?cation Search 
USPC .......... .. 514/332, 333, 359; 546/186; 548/518 
See application ?le for complete search history. 
(56) References Cited 
FOREIGN PATENT DOCUMENTS 
WO WO2007/076ll2 * 7/2007 
W0 WO 2007/094912 * 8/2007 
OTHER PUBLICATIONS 
......... .. A61K 31/444 
Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, and Crooks PA, 
“Tris-aZaaromatic quaternary ammonium salts: Novel templates as 
antagonists at nicotinic receptors mediating nicotine-evoked 
dopamine release,” Bioorganic & Medicinal Chemistry Letters, Dec. 
2007, 17(24), 6701-6706 (Epub Oct. 22, 2007).* 
* cited by examiner 
Primary Examiner * Paul Zarek 
(74) Attorney, Agent, or Firm * CroWell & Moring LLP 
(57) ABSTRACT 
Provided are tetrakis-quatemary ammonium compounds 
Which are modulators of nicotinic acetylcholine receptors. 
Also provided are methods of using the compounds for modu 
lating the function of a nicotinic acetylcholine receptor, and 
for the prevention and/ or treatment of central nervous system 
disorders, substance use and/or abuse, and or gastrointestinal 
tract disorders. 
19 Claims, 2 Drawing Sheets 
_ 
, / 
222086 B‘? 
31, 2007. 
(51) Int. Cl. 
A61K 31/44 (2006.01) 
A61K 31/41 (2006.01) 
C07D 211/00 (2006.01) 
C07D 207/00 (2006.01) 
1.5 
lC5o=0.056 i 0.045pM 
5 E_ lmax = 52 i 4 % 
t 1 o 
m . 
> 
2. 
I 
“L 
E 0.5 
4; 
Q 
' 
O.O-—1—I - - - -' - ‘ 
control -9 -8 -7 -6 -5 
log [ZZ 2086] (M) 

US. Patent Jan. 14, 2014 Sheet 2 of2 US 8,629,163 B2 
As; 58NNHm2
.5 H8u 52s
:1 83. H.83n 2
.IrI" [llloo 
I 
"o. 
o 
US 8,629,163 B2 
1 
TE TRAKIS-QUATERNARY AMMONIUM 
SALTS AND METHODS FOR MODULATING 
NEURONAL NICOTINIC AC TEYLCHOLINE 
RECEPTORS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to US. Provisional Appli 
cation Ser. No. 61/001,196 ?led Oct. 31, 2007, the entire 
contents of Which are herein expressly incorporated herein by 
reference 
FIELD OF THE INVENTION 
The invention relates to tetrakis-quaternary ammonium 
salts and their use in modulating nicotinic acetylcholine 
receptors. 
BACKGROUND OF THE INVENTION 
S(—)-Nicotine (NIC) activates presynaptic and postsynap 
tic neuronal nicotinic receptors that evoke the release of neu 
rotransmitters from presynaptic terminals and that modulate 
the depolariZation state of the postsynaptic neuronal mem 
brane, respectively. Thus, nicotine produces its effect by 
binding to a family of ligand-gated ion channels, stimulated 
by acetylcholine (ACh) or nicotine Which causes the ion 
channel to open and cations to ?ux With a resulting rapid 
(millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of tWo types of 
subunits, 0t and [3, and assemble as heteromeric receptors With 
the general stoichiometry of 2a and 3[3 or as homomeric 
receptors With 5a subunits. Nine subtypes of the ot subunit 
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are 
found in the central nervous system. The mo st common nico 
tinic receptor subtype in the brain is composed of tWo (X4 and 
three [32 subunits, i.e., (X462. These subunits display different, 
but overlapping, patterns of expression in the brain. Examples 
of heteromeric receptor subtypes include (X462, (X362, (X3 [34, 
(X662, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and 
others. The predominant homomeric subtype includes (x7, but 
other combinations have also been proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combina 
tions of assemblies of subunits into functional receptor pro 
teins, Which affords a Wide diversity of pharmacological 
speci?city. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3H]ACh. It has 
been estimated that over 90% of [3H]NIC binding in the brain 
is due to association With the heteromeric receptor that is 
composed of (X4 and [32 subunits. Also abundant in the central 
nervous system are the homomeric receptors labeled by [3 H] 
methyllycaconitine (MLA), Which has high af?nity for the (X7 
nicotinic receptor subtype. Nicotinic receptor subtypes can 
be studied using functional assays, such as NIC-evoked neu 
rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H] 
norepinephrine (NE) release, [3H]serotonin (5-HT) release, 
[3H]gamma-aminobutyric acid (GABA) release and [3 H] 
glutamate release) from superfused rat brain slices. Nicotinic 
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receptors are located in the cell body and terminal areas of 
these neurotransmitter systems. NIC facilitates neurotrans 
mitter release from nerve terminals. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of inter 
est in developing novel, subtype-selective agonists and/or 
antagonists. Some of these agonists are currently being evalu 
ated in clinical trials for cognitive enhancement and neuro 
protective effects, potentially bene?cial for disease states 
such as schizophrenia, AlZheimer’s and Parkinson’s disease. 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the fol 
loWing structure are provided. 
(CH2)m3 
[3 
(CHZM 
Each X9 is independently an organic or inorganic anion. 
Q is a phenyl group substituted at the 1-, 2-, 3- and 4-po 
sitions, at the 1-, 2-, 3- and 5-positions, or at the 1-, 2-, 4- and 
5-positions. 
The values for m1, m2, m3 and m4 are each independently 
0, 1, 2, 3, 4 or 5. 
The values for n1, n2, n3 and n4 are each independently 1, 
2, 3, 4 or 5. 
L1, L2, L1 and L4 are each independently selected from 
4CH2CH2i, cis iCH:CHi, trans iCH:CHi, 
%ECi, iSiCHZi, %H2iSi, iSeiCHzi, 
%H2iSei, iO%H2i, iCHziOi, iNHi 
CHzi, iCH2iNHi, iN(loWer alkyl)-CH2i, 4CH2i 
N(loWer alkyl)-, iN:CHi, 4CH:Ni or iN:Ni. 
Z1, Z2, Z3 and Z4 are each independently ?ve or six mem 
bered rings as shoWn in formulas (HA) and (IIB), Wherein 
each ring of Z1, Z2, Z3 and Z4 has one, tWo or three nitrogen 
atoms. 
US 8,629,163 B2 
A1 is carbon or nitrogen, provided that WhenAl joins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is absent, 
and When A1 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R4 and R9 are absent. 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom With an unsaturated bond or is a nitrogen, R10 is absent, 
and When A2 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R10 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom With an unsaturated bond or is a nitrogen, R1 l is absent, 
and When A3 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R6 and R11 are absent. 
A4 is carbon or nitrogen, provided that When A4 j oins a ring 
atom With an unsaturated bond or is a nitrogen, R12 is absent, 
and When A4 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R7 and R12 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom With an unsaturated bond or is a nitrogen, R13 is absent, 
and When A5 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R8 and R13 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom With an unsaturated bond or is a nitrogen, R19 is absent, 
and When A6 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R15 and R19 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom With an unsaturated bond or is a nitrogen, R20 is absent, 
and When A7 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R16 and R20 are absent. 
A8 is carbon or nitrogen, provided that When A8 joins a ring 
atom With an unsaturated bond or is a nitrogen, R21 is absent, 
and When A8 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R17 and R21 are absent. 
A9 is carbon or nitrogen, provided that When A9 joins a ring 
atom With an unsaturated bond or is a nitrogen, R22 is absent, 
and When A9 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R14 and R22 are absent. 
R14 or R23 is absent When any of the bonds to the ammo 
nium nitrogen is unsaturated, and R14 or R23 is a straight chain 
or branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16, 
R17, R18, R19, R20, R21, and R22, When present, are each 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, SOYl, SOZYI, SOZOYl or SO2NHY1, 
where Y1 is selected from hydrogen, loWer alkyl, alkenyl, 
alkynyl or aryl, and where Y1 is not hydrogen in SOYl and if 
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju 
gated With a heteroatom; COY2, Where Y2 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub 
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
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tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, or substituted heterocyclic, and Where if Y2 com 
prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated With the carbonyl group; 0Y3, Where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y3 comprises alk 
enyl or alkynyl, the site of unsaturation is not conjugated With 
the oxygen; NY4Y5 , Where Y4 and Y5 are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y4 orY5 comprises 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With the nitrogen; SY6, Where Y6 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla 
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk 
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or 
substituted heterocyclic, and Where ifY6 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6 
together With A2 and A3, or R15 and R1 6 together With A6 and 
A7 or R1 6 and R1 7 together WithA7 andA8 independently form 
a three to eight member cyclolkane, substituted cycloalkane, 
cycloalkene, substituted cycloalkene, aryl, substituted aryl, 
heterocycle With one to three hetero atoms in the ring, or 
substituted heterocycle With one to three hetero atoms in the 
ring. 
In another embodiment, a composition is provided com 
prising a pharmaceutically acceptable carrier and a com 
pound as described above. 
In another embodiment, a method is provided for selec 
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating a central nervous system associated disor 
der comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating substance use and/or abuse comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating gastrointestinal tract disorders comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
Other methods, features and advantages of the present 
invention Will be or become apparent to one With skill in the 
art upon examination of the folloWing detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included Within this description, be Within the 
scope of the present invention, andbe protected by the accom 
panying claims. 
US 8,629,163 B2 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the concentration dependent inhibition by 
compounds ZZ-208G (FIG. 1A) and ZZ-280F (FIG. 1B) on 
the effect of nicotine to evoke [3H]dopamine release. 
DETAILED DESCRIPTION OF INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no Way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherWise. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to Which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection With the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The term “nicotinic acetylcholine receptor” refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine Which also bind to nicotine. The term “nicotinic 
acetylcholine receptor” includes the term “neuronal nicotinic 
acetylcholine receptor.” 
The terms “subtype of nicotinic acetylcholine receptor,” 
and “nicotinic acetylcholine receptor subtype” refer to vari 
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or hetero 
meric complex, or multiple homomeric or heteromeric com 
plexes. 
The term “agonist” refers to a substance Which interacts 
With a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term “partial agonist” refers to a substance Which 
interacts With and activates a receptor to a lesser degree than 
an agonist. 
The term “antagonist” refers to a substance Which interacts 
With and decreases the extent or duration of a physiological 
response of that receptor. 
The terms “disorder,” “disease,” and “condition” are used 
inclusively and refer to any status deviating from normal. 
The term “central nervous system associated disorders” 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated With the alteration of normal 
neurotransmitter release in the brain. 
The term “loWer alkyl” refers to straight or branched chain 
alkyl radicals having in the range of l to 4 carbon atoms. 
The term “alkyl” refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and “substituted alkyl” 
refers to alkyl radicals further bearing one or more substitu 
ents including, but not limited to, hydroxy, alkoxy (of a loWer 
alkyl group), mercapto (of a loWer alkyl group), aryl, hetero 
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car 
boxyl, carbamate, sulfonyl, and sulfonamide. 
The term “cycloalkyl” refers to cyclic ring-containing moi 
eties containing 3 to 8 carbon atoms, and “substituted 
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cycloalkyl” refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term “alkenyl” refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and “substituted 
alkenyl” refers to alkenyl groups further bearing one or more 
substituents as set forth above. 
The term “alkynyl” refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and “substituted 
alkynyl” refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term “aryl” refers to aromatic groups having 6 to 24 
carbon atoms, and “substituted aryl” refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term “alkylaryl” refers to alkyl-substituted aryl 
groups, and “substituted alkylaryl” refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkyl” refers to aryl-substituted alkyl 
groups, and “substituted arylalkyl” refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkenyl” refers to aryl-substituted alkenyl 
groups, and “substituted arylalkenyl” refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term “arylalkynyl” refers to aryl-substituted alkynyl 
groups, and “substituted arylalkynyl” refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term “heterocyclic” refers to cyclic moieties contain 
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and “substituted heterocyclic” 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term “acyl” refers to alkyl-carbonyl groups, and “sub 
stituted acyl” refers to acyl groups further bearing one or 
more substituents as set forth above. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide groups. 
It is understood that in all substituted groups de?ned above, 
polymers arrived at by de?ning sub stituents With further sub 
stituents to themselves (e. g. substituted aryl having a substi 
tuted aryl group as a substituent Which is itself substituted 
With a substituted aryl group, etc.) are not intended for inclu 
sion herein. In such cases, the maximum number of such 
substituents is three. That is to say that each of the above 
de?nitions is constrained by a limitation that, for example, 
substituted aryl groups are limited to -substituted aryl-(sub 
stituted aryl)-sub stituted aryl. 
Compounds of the present invention are tetrakis-quater 
nary ammonium salts corresponding to Formula (I): 
Each X9 is independently an organic or inorganic anion. 
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Q is a phenyl group substituted at the 1-, 2-, 3- and 4-po 
sitions, at the 1-, 2-, 3- and 5-positions, or at the 1-, 2-, 4- and 
5-positions. 
The values for m1, m2, m3 and m4 are each independently 
0, 1, 2, 3, 4 or 5. 
The values for n1, n2, n3 and n4 are each independently 1, 
2, 3, 4 or 5. 
L1, L2, L3 and L4 are each independently selected from 
iCH2CH2i, cis 4CH:CHi, trans 4CH:CHi, 
*CECi, iS%H2i, %H2iSi, iSeiCH2i, 
iCHZiSei, iO%H2i, iCHziOi, iNHi 
CHzi, iCHZiNHi, iN(loWer alkyl)-CH2i, 4CH2i 
N(loWer alkyl)-, iN:CHi, 4CH:Ni or iN:Ni. 
Z1, Z2, Z3 and Z4 are each independently ?ve or six mem 
bered rings as shown in formulas (11A) and (11B), Wherein 
each ring of Z1, Z2, Z3 and Z4 has one, tWo or three nitrogen 
atoms. 
(HA) 
(HE) 
A1 is carbon or nitrogen, provided that WhenAl joins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is absent, 
and When A1 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R4 and R9 are absent. 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom With an unsaturated bond or is a nitrogen, R10 is absent, 
and When A2 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R10 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom With an unsaturated bond or is a nitrogen, R1 1 is absent, 
and When A3 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R6 and R11 are absent. 
A4 is carbon or nitrogen, provided that When A4 j oins a ring 
atom With an unsaturated bond or is a nitrogen, R12 is absent, 
and When A4 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R7 and R12 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom With an unsaturated bond or is a nitrogen, R13 is absent, 
and When A5 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R13 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom With an unsaturated bond or is a nitrogen, R19 is absent, 
and When A6 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R15 and R19 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom With an unsaturated bond or is a nitrogen, R20 is absent, 
and When A7 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R16 and R20 are absent. 
A8 is carbon or nitrogen, provided that When A8 joins a ring 
atom With an unsaturated bond or is a nitrogen, R21 is absent, 
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and When A8 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R17 and R21 are absent. 
A9 is carbon or nitrogen, provided that WhenA9 joins a ring 
atom With an unsaturated bond or is a nitrogen, R22 is absent, 
and When A9 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R14 and R22 are absent. 
R14 or R23 is absent When any of the bonds to the ammo 
nium nitrogen is unsaturated, and R14 or R23 is a straight chain 
or branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16’ 
R17, R18, R19, R20, R21, and R22, When present, are each 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, SOYl, SOZYI, SOZOYl or SO2NHY1, 
where Y1 is selected from hydrogen, loWer alkyl, alkenyl, 
alkynyl or aryl, and WhereYl is not hydrogen in SOYl and if 
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju 
gated With a heteroatom; COY2, Where Y2 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub 
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, or substituted heterocyclic, and Where if Y2 com 
prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated With the carbonyl group; 0Y3, Where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y3 comprises alk 
enyl or alkynyl, the site of unsaturation is not conjugated With 
the oxygen; NY4Y5 , Where Y4 and Y5 are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y4 orY5 comprises 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With the nitrogen; SY6, Where Y6 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla 
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk 
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or 
substituted heterocyclic, and Where ifY6 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6 
together With A2 and A3, or R15 and R1 6 together With A6 and 
A7, or R16 and R17 together With A7 and A8 independently 
form a three to eight member cyclolkane, substituted cycloal 
kane, cycloalkene, substituted cycloalkene, aryl, substituted 
aryl, heterocycle With one to three hetero atoms in the ring, or 
substituted heterocycle With one to three hetero atoms in the 
ring. 
For example, Z1, Z2, Z1 and Z4 include pyrrole, pyrrolidine, 
pyraZole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine, 
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piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet 
rahydroisoquinoline, pyraZine, piperaZine, pyridaZine, and 
triaZine. 
As another example, R4, R5, R6, R7, R8, R9, R10, R11, R12, 
R13, R15,R16,Rl7R18, R19, R2O,R21, and R22, include hydro 
gen, methyl, ethyl, propyl, butyl, tri?uoromethyl, hydroxym 
ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, phenyl, 
benZyl, pyrrolidine, N-alkyl pyrrolidine (for example Where 
the alkyl chain is methyl, ethyl or propyl), unsaturated pyr 
rolidine, unsaturated N-alkyl pyrrolidine (for example Where 
the alkyl chain is methyl, ethyl or propyl), aZiridine, N-methyl 
aZiridine, aZetidine, N-methyl aZetidine, unsaturated aZeti 
dine, unsaturated N-methyl aZetidine, piperidine, N-methyl 
piperidine, unsaturated piperidine, unsaturated N-methyl 
piperidine, aZepane, N-methyl aZepane, unsaturated aZepane, 
unsaturated N-methyl aZepane, aZocane, N-methyl aZocane, 
unsaturated aZocane, unsaturated N-methyl aZocane, l-aZa 
bicyclo[3.2.l]octane, l-aZa-bicyclo[2.2.l]heptane, 8-me 
thyl-8-aZa-bicyclo[3.2.l]octane, l-aZa-tricyclo[3.3.l.l3’7] 
decane, methyl cycloalkyl, methyl substituted cycloalkyl, 
methylpyrrolidine, methyl N-alkyl pyrrolidine (for example 
Where the alkyl chain is methyl, ethyl or propyl), methyl 
unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrroli 
dine (for example Where the alkyl chain is methyl, ethyl or 
propyl), methyl aZiridine, methyl N-methyl aZiridine, methyl 
aZetidine, methyl N-methyl aZetidine, methyl unsaturated 
aZetidine, methyl unsaturated N-methyl aZetidine, methyl 
piperidine, methyl N-methyl piperidine, methyl unsaturated 
piperidine, methyl unsaturated N-methyl piperidine, methyl 
aZepane, methyl N-methyl aZepane, methyl unsaturated 
aZepane, methyl unsaturated N-methyl aZepane, methyl aZo 
cane, methyl N-methyl aZocane, methyl unsaturated aZocane, 
methyl unsaturated N-methyl aZocane, methyl-l -aZa-bicyclo 
[3.2.1]octane, methyl-l-aZa-bicyclo[2.2.l]heptane, 8-me 
thyl-8-aZa-bicyclo[3.2.l]octane, and methyl-l-aZa-tricyclo 
[3.3.l.l3’7]decane. 
As a further example, When R4 and R5 together WithAl and 
A2, or R5 and R6 together With A2 and A3, or R15 and R16 
together With A6 and A7, or R16 and R17 together With A7 and 
A8 independently form a three to eight-membered ring, that 
ring may be a heterocycle containing up to three hetero atoms 
(for example nitrogen, oxygen or sulfur) in the ring, and 
further may be substituted With one or more substituents. For 
example, possible rings include benZene, pyridine, pyran, 
indene, isoindene, benZofuran, isobenZofuran, benZo [b] 
thiophene, benZo[c]thiophene, indole, indolenine, isoindole, 
cyclopental[b]pyridine, pyrano[3,4-b]pynrole, indaZole, 
indoxaZine, benZoxaZole, anthranil naphthalene, tetralin, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, 
isochromen-3-one, quinoline, isoquinoline, 5,6,7,8-tetrahy 
dro-isoquinoline, cinnoline, quinaZoline, naphthyrdine, 
pyrido[3,4-b]-pyridine, pyridol[3,2-b]pyridine, pyrido[4,3, 
b]-pyridine, benZoxaZine, anthracene, phenanthrene, phe 
nalene, ?uorene, caraZole, xanthene, acnidine, octahydro-[l] 
pyridine, l-methyloctahydro-[l]pyridine, octahydroindole, 
l-methyloctahydro-indole, octahydro-cyclopenta[b]pyrrole, 
l-methyloctahydro-cyclopenta[b]pyrrole, decahydroquino 
line, and l-methyldecahydroquinoline. 
X9, for example, includes F‘, Cl‘, Br‘, I‘, N02‘, H804‘, 
S04“, HPO4_, PO42“, methanesulfonate, tri?uoromethane 
sulfate, p-toluenesulfonate, benZenesulfonate, salicylate, 
proprionate, ascorbate, aspartate, fumarate, galactarate, 
maleate, citrate, glutamate, glycolate, lactate, malate, male 
ate, tartrate, oxalate, succinate, or similar pharmaceutically 
acceptable organic acid addition salts, including the pharma 
ceutically acceptable salts listed in the Journal of Pharmaceu 
tical Sciences Volume 66, page 2, 1977, Which are hereby 
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incorporated by reference. The above salt forms may be in 
some cases hydrates or solvates With alcohols and other sol 
Vents. 
In a compound of Formula (I), preferably the phenyl ring of 
Q is substituted at the l-, 2-, 4- and 5-positions. 
In a compound of Formula (I), preferably A1, A2, A3, A4, 
and A5 are carbon. 
In a compound of Formula (I), preferably Z1, Z2, Z3 and Z4 
are substituted, six-membered, aromatic rings. More prefer 
ably, Z1, Z2, Z3 and Z4 are substituted pyridinium rings. 
In a compound of Formula (I), preferably R4 is hydrogen. 
In a compound of Formula (I), preferably R5 is hydrogen, 
alkyl, hydroxyalkyl, phenyl, benZyl, l-methyl-2-pyrrolidi 
nyl, or forms a six-membered ring With A2, A3 and R6. More 
preferably, R5 is hydrogen, methyl, hydroxypropyl, phenyl, 
benZyl, l-methyl-2-pyrrolidinyl, forms a phenyl group With 
A2, A3 and R6, or forms a cyclohexyl group With A2, A3 and 
R6. 
In a compound of Formula (I), preferably R6 is hydrogen, 
alkyl, forms a phenyl group With A2, A3 and R5, or forms a 
cyclohexyl group With A2, A3 and R5. More preferably, R6 is 
hydrogen, methyl, forms a phenyl group With A2, A3 and R5 , 
or forms a cyclohexyl group With A2, A3 and R5 . 
In a compound of Formula (I), preferably R7 is hydrogen or 
alkyl. More preferably, R7 is hydrogen or methyl. 
In a compound of Formula (I), preferably R8 is hydrogen. 
In a compound of Formula (I), preferably ml, m2, m3 and 
m4:0. 
In a compound of Formula (I), preferably n1, n2, n3 and 
n4:3. 
In a compound of Formula (I), preferably L1, L2, L3 and L4 
are %H2%H2i or iCECi. 
In a compound of Formula (I), preferably X9 is a halogen. 
More preferably, X9) is bromide. 
In one embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted; 
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3; 
Wherein L is 4CH2CH2i or iCECi; wherein Z1, Z2, Z3 
and Z4 are pyridinium rings; Wherein R4 is hydrogen; Wherein 
R5 is hydrogen, methyl, hydroxypropyl, phenyl, benZyl, 
l-methyl-2-pyrrolidinyl, forms a phenyl group With A2, A3 
and R6, or forms a cyclohexyl group With A2, A3 and R6; 
Wherein R6 is hydrogen, methyl, forms a phenyl group With 
A2, A3 and R5, or forms a cyclohexyl group With A2, A3 and 
R5; and Wherein X9 is Br. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted; 
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3; 
Wherein L is iCHZCHZi; wherein Z1, Z2, Z3 and Z4 are 
pyridinium rings; Wherein R4 is hydrogen; Wherein R5 is 
hydrogen, methyl, hydroxypropyl, phenyl, benZyl, l-methyl 
2-pyrrolidinyl, forms a phenyl group With A2, A3 and R6, or 
forms a cyclohexyl group With A2, A3 and R6; Wherein R6 is 
hydrogen, methyl, forms a phenyl group With A2, A3 and R5, 
or forms a cyclohexyl group With A2, A3 and R5 ; and Wherein 
X9 is Br. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted; 
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3; 
Wherein L is 4CECi; wherein Z1, Z2, Z3 and Z4 are pyri 
dinium rings; Wherein R4 is hydrogen; Wherein R5 is hydro 
gen, methyl, hydroxypropyl, phenyl, benZyl, l-methyl-2-pyr 
rolidinyl, forms a phenyl group With A2, A3 and R6, or forms 
a cyclohexyl group With A2, A3 and R6; Wherein R6 is hydro 
gen, methyl, forms a phenyl group With A2, A3 and R5, or 
forms a cyclohexyl group With A2, A3 and R5; and Wherein 
X9 is Br. 
US 8,629,163 B2 
11 
Exemplary compounds of the present invention include: 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(3-methylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(4-methylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(3,4-dimethylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(3,5-dimethylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
nicotinium) tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis[4-pentyn-1-yl 
(5,6,7,8-tetrahydroisoquinolinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(3-phenyl-pyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis(4-pentyn-1-yl 
isoquinolinolinium)tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl 
(3-benZyl-pyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis {4-pentyn-1 
yl- [3 -(3 -hydroxypropyl)-pyridinium] }tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3 
methylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(4 
methylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3,4 
dimethylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3,5 
dimethylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl 
(nicotinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3 
(3-hydroxypropanyl)pyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(iso 
quinolinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3 
benZylpyridinium)]tetrabromide; 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3 
phenylpyridinium)]tetrabromide; and 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(5,6, 
7,8-tetrahydroisoquinolinium)]tetrabromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as Well as racemic 
mixtures. The compounds can be separated into substantially 
optically pure compounds. The compounds of the present 
invention can be prepared by any applicable method knoWn 
by those of skill in the art, including synthesis from corre 
sponding free bases by reaction With an appropriate alkyl 
bromide. 
The compounds of the invention are nicotinic acetylcho 
line receptor agents. Thus, they may augment or inhibit [3 H] 
nicotine binding, [3H]MLA binding, evoke or inhibit neu 
rotransmitter release, and/or evoke or inhibit the ?ux of ions 
through the nicotinic receptor. Moreover, the compounds of 
the invention may act either at presynaptic sites or postsyn 
aptic sites, for example, at a postsynaptic acetylcholine recep 
tor containing an (X7 subunit. When acting at a postsynaptic 
site, neurotransmitter release per se is not altered. Rather, the 
compounds of the invention may act by interacting With a 
postsynaptic acetylcholine receptor to change the membrane 
potential of the cell, thereby increasing or decreasing the 
likelihood of ?ring an action potential. Alternatively, interac 
tion of a compound of the invention With a postsynaptic 
acetylcholine receptor may result in the alteration of one or 
more second messenger systems Within the cell so as to 
decrease or increase the nicotinic cholinergic response. 
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In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agonist or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agonist or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
Central nervous system disorders Which may be treated 
according to the method of the present invention include 
AlZheimer’s disease, dementia, cognitive dysfunctions (in 
cluding disorders of attention, focus and concentration), 
attention de?cit disorders, affective disorders, extrapyrami 
dal motor function disorders, Parkinson’s disease, progres 
sive supramolecular palsy, Huntington’s disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis 
orders, dysregulation of food intake, disorders of nociception, 
pain, including nociceptive pain and neuropathic pain, mood 
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and emotional disorders, depression, panic anxiety, psycho 
sis, schizophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating sub stance 
use and/or abuse comprising administering to a mammalian 
subject in need thereof a therapeutically effective amount of a 
compound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptors. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet 
amine abuse, MDMA (methylenedioxymethamphetamine) 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating gastrointestinal tract 
disorders comprising administering to a mammalian subject 
in need thereof a therapeutically effective amount of a com 
pound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue, or may increase 
or prolong the release of a neurotransmitter from a peripheral 
nervous system tissue, or may act directly on a gastrointesti 
nal tract tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine recep 
tor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans 
mitter from a central nervous system tissue, or may decrease 
the extent or duration of the release of a neurotransmitter from 
a peripheral nervous system tissue, or may act directly on a 
gastrointestinal tract tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutyric acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting With a postsynaptic ace 
tylcholine receptor to change the membrane potential of the 
cell thereby increasing or decreasing the likelihood of ?ring 
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an action potential, or to alter one or more second messenger 
systems Within the cell so as to decrease or increase the 
nicotinic cholinergic response. 
Gastrointestinal disorders Which may be treated according 
to the method of the present invention include irritable boWel 
syndrome, colitis, diarrhea, constipation, gastric acid secre 
tion or ulcers. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along With suit 
able carriers or excipients, as is Well knoWn in the art. For 
example, a pharmaceutical composition of the invention may 
include a conventional additive, such as a stabiliZer, buffer, 
salt, preservative, ?ller, ?avor enhancer and the like, as knoWn 
to those skilled in the art. Exemplary buffers include phos 
phates, carbonates, citrates and the like. Exemplary preserva 
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter 
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro 
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington’s Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin 
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as Well as intrathe 
cal, direct intraventricular, intravenous, intraperitoneal, intra 
nasal, or intraocular injections. In addition, the agent or com 
position thereof may be administered sublingually or via a 
spray, including a sublingual tablet or a sublingual spray. The 
agent or composition thereof may be administered in a local 
rather than a systemic manner. For example, a suitable agent 
can be delivered via injection or in a targeted drug delivery 
system, such as a depot or sustained release formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods Well-knoWn in 
the art, such as by conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophiliZing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin 
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in physi 
ologically compatible buffers such as Hanks’ solution, Ring 
er’ s solution, or physiological saline buffer. For transmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally knoWn in the art. In a preferred embodiment of 
the present invention, the present compounds are prepared in 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
combining the active compounds With pharmaceutically 
acceptable carriers Well knoWn in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen 
sions and the like, for oral ingestion by a subject. The com 
pounds may also be formulated in rectal compositions such as 
suppositories or retention enemas, e.g., containing conven 
tional suppository bases such as cocoa butter or other glyc 
erides. 
Pharmaceutical preparations for oral use can be obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux 
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
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excipients are, in particular, ?llers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maize starch, Wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel 
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin 
tegrating agents may be added, such as cross-linkedpolyvinyl 
pyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, Wetting agents such as sodium dodecyl 
sulfate may be included. 
Dragee cores are provided With suitable coatings. For this 
purpose, concentrated sugar solutions may be used, Which 
may optionally contain gum arabic, talc, polyvinyl pyrroli 
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identi?cation or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-?t capsules made of gelatin, as Well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-?t capsules can contain the 
active ingredients in admixture With ?ller such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap 
sules, the active compounds may be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraf?n, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven 
tion can be administered transdermally, such as through a skin 
patch, or topically. In one aspect, the transdermal or topical 
formulations of the present invention can additionally com 
prise one or multiple penetration enhancers or other effectors, 
including agents that enhance migration of the delivered com 
pound. Transderrnal or topical administration could be pre 
ferred, for example, in situations in Which location speci?c 
delivery is desired. Methods of transdermal delivery include 
microneedle transdermal delivery. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, With the use of a suitable propellant, e.g., 
dichlorodi?uoromethane, trichloro?uoromethane, dichlo 
rotetra?uoroethane, carbon dioxide, or any other suitable gas. 
In the case of a pressurized aerosol, the appropriate dosage 
unit may be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insuf?ator may be formulated. 
These typically contain a poWder mix of the compound and a 
suitable poWder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e. g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, With an added preservative. The com 
positions may take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as suspending, stabilizing and/or dis 
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in Water 
soluble form. 
Suspensions of the active compounds may also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer 
ides, or liposomes. Aqueous injection suspensions may con 
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tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension may also contain suitable stabiliz 
ers or agents that increase the solubility of the compounds to 
alloW for the preparation of highly concentrated solutions. 
Alternatively, the active ingredient may be in poWder form for 
constitution With a suitable vehicle, e.g., sterile pyrogen-free 
Water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated With suitable poly 
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are Well knoWn in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a Water-miscible organic polymer, and an aqueous 
phase. The co-solvent system may be the VPD co-solvent 
system. VPD is a solution of 3% W/v benzyl alcohol, 8% W/v 
of the nonpolar surfactant polysorbate 80, and 65% W/v poly 
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (VPDzSW) consists of VPD 
diluted 1:1 With a 5% dextrose in Water solution. This co 
solvent system is effective in dissolving hydrophobic com 
pounds and produces loW toxicity upon systemic administra 
tion. Naturally, the proportions of a co-solvent system may be 
varied considerably Without destroying its solubility and tox 
icity characteristics. Furthermore, the identity of the co-sol 
vent components may be varied. For example, other loW 
toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly 
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars 
or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic mol 
ecules may be employed. Liposomes and emulsions are Well 
knoWn examples of delivery vehicles or carriers for hydro 
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus 
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained 
release materials are established and available to those of skill 
in the art. Sustained-release capsules may, depending on their 
chemical nature, release the compounds for a feW Weeks up to 
over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabilization may be employed. 
For any composition used in the present methods of treat 
ment, a therapeutically effective dose can be estimated ini 
tially using a variety of techniques Well knoWn in the art. For 
example, in a cell culture assay, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the IC5O as determined in cell culture. Dosage 
ranges appropriate for human subjects can be determined, for 
example, using data obtained from cell culture assays and 
other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent Which results in amelioration of symp 
toms or a prolongation of survival in a subject. Toxicity and 
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therapeutic e?icacy of such molecules can be determined by 
standard pharmaceutical procedures in cell cultures or experi 
mental animals, e. g., by determining the LD5O (the dose lethal 
to 50% of the population) and the ED5O (the dose therapeuti 
cally effective in 50% of the population). The dose ratio of 
toxic to therapeutic effects is the therapeutic index, Which can 
be expressed as the ratio LDSO/EDSO. Agents that exhibit high 
therapeutic indices are preferred. 
Dosages preferably fall Within a range of circulating con 
centrations that includes the ED5O With little or no toxicity. 
Dosages may vary Within this range depending upon the 
dosage form employed and the route of administration uti 
liZed. The exact formulation, route of administration, and 
dosage should be chosen, according to methods knoWn in the 
art, in vieW of the speci?cs of a subject’s condition. 
The amount of agent or composition administered Will, of 
course, be dependent on a variety of factors, including the sex, 
age, and Weight of the subject being treated, the severity of the 
af?iction, the manner of administration, and the judgment of 
the prescribing physician. Compounds of the present inven 
tion Will generally be administered in an amount ranging 
from about 1><10_5 to 100 mg/kg/day, With amounts in the 
range of about 1><10_2 to 1 mg/kg/day being preferred. 
The present compositions may, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
forms containing the active ingredient. Such a pack or device 
may, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device may be accompa 
nied by instructions for administration. Compositions com 
prising a compound of the invention formulated in a compat 
ible pharmaceutical carrier may also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi 
cated condition. 
These and other embodiments of the present invention Will 
readily occur to those of ordinary skill in the art in vieW of the 
disclosure herein, and are speci?cally contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
folloWing examples, Which are intended to be purely exem 
plary of the invention. The present invention is not limited in 
scope by the exempli?ed embodiments, Which are intended as 
illustrations of single aspects of the invention only. Any meth 
ods that are functionally equivalent are Within the scope of the 
invention. Various modi?cations of the invention in addition 
to those described herein Will become apparent to those 
skilled in the art from the foregoing description. Such modi 
?cations fall Within the scope of the appended claims. 
Example 1 
Preparation of 1,2,4,5-tetraiodobenZene 
© IUI l 1 
Periodic acid (2.56 g, 11.2 mmol) Was dissolved With stir 
ring in concentrated H2SO4 (60 mL). Potassium iodide (5.58 
g, 33.6 mmol) Was crushed and added to the clear solution. 
After about 30 min of stirring, the dark mixture Was placed in 
an ice bath. The aromatic substrate (C6H5, 1 mL, 11.2 mmol) 
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Was then added sloWly. The reaction Was alloWed to stir to 
room temperature for 1 day and poured onto crushed ice. The 
resulting solid Was collected by suction ?ltration and Washed 
Well With methanol to remove iodine. The crude lavender 
poWder (5.4 g 82% yield) Was crystalliZed from 2-methoxy 
ethanol, giving 1,2,4,5-tetraiodobenZene (71% yield) as 
White needles, mp 252-2550 C. 1H NMR (Me2SO-d6) 
6 8.32 (s); 13C NMR (Me2SO-d6) 147.1, 108.5 ppm. 
Example 2 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis(4-pentyn-ol) 
HO OH % % 
HO % % OH 
To a degassed solution of 1 ,2,4,5-tetraiodobenZene (5.81 g, 
0.01 mol) in DMF-Et3N (100 mL, 1:1) Were added 
Pd(PPh3)2Cl2 (350 mg. 0.5 mmol), Cul (200 mg, 1.2 mmol), 
and 4-pentyn-1-ol (4.2 g, 0.05 mol) Was added drop-Wise. The 
mixture Was stirred under N2 at room temperature for 24 h. 
The solution Was poured into Water (400 mL). The mixture 
Was extracted With CH2Cl2 (3x200 mL). The combined 
organic phases Were Washed With 5% HCl and brine, dried 
over Na2SO4, and concentrated under vacuum. The residue 
Was puri?ed by silica gel column chromatography using 
CH2Cl2-MeOH (10:1, v/v) as eluent to afford tetramer (3.34 
g, 82%): 1H NMR (300 MHZ, CD3Cl+CO3OD 6 ppm), 7.30 
(s, 2H), 3.72 (t, 1:63 HZ, 8H), 2.52 (t, J:7.2 HZ, 8H), 1.80 (p, 
1:66 HZ, 8H) ppm. 
Example 3 
Preparation of 5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl) 
tetraki s( 1 -bromo-4 -p entyne) 
HO % % OH 
HO % % OH 
Br % % Br 
Br % % Br 
5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl)tetrakis-4 -pentyn-ol 
(2.05 g, 5.03 mmol) and carbon tetrabromide (7.41 g, 22.35 
mmol) Were dissolved in dry methylene chloride (100 mL) 
and cooled to 00 C. Triphenyl phosphine (6.16 g, 23 .47 mmol) 
Was added portion-Wise and the mixture Was stirred at RT. 
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After the starting alcohol Was consumed methanol Was added 
and the mixture Was stirred for an additional 5 minutes. The 
mixture concentrated and Was treated With hexanes (500 mL) 
and then ?ltered through a short silica gel column, Washed 
With ethylacetate/hexanes (1/4). The combined organic sol- 5 
vents Were evaporated to dryness under reduced pressure. The 
resulting residue Was puri?ed by column chromatography 
(hexanes) to afford 2.84 g of the title compound. Yield: 89%. 
lHNMR (300 MHZ, CDCl3) 6 7.39 (s, 2H), 3.62 (t, 1:63 HZ, 
8H), 2.67 (t, 1:66 HZ, 8H), 1.14 (p, 1:66 HZ, 8H) ppm. 
Example 4 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis-(pentan-l -ol) 
HO OH 
20 
HO OH 
25 
HO OH 
HO OH 
5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-4-pentyn-1-ol 
(2.01 g, 4.95 mmol) Was dissolved in methanol (30 mL) and 
10% Pd/C (5% W/W) Was added. The resulting mixture Was 
hydrogenated on a Parr hydrogenation apparatus (45 psig) for 
4 hrs. The catalyst Was removed by ?ltration through a Celite 
pad. The ?lter cake Was rinsed With methanol, and the com 
bined organic liquors Were concentrated under reduced pres 
sure. The crude product Was puri?ed by column chromatog 
raphy (CHCl3:MeOH, 10: 1) to afford 1.97 g of the title 
compound. Yield: 95%. 1H NMR (300 MHZ, CDCl3) 6 6.81 
(s, 3H), 3.62 (t, 1:63 HZ, 6H), 2.57 (t, 1:75 HZ, 6H), 1.53 
1.70 (m, 12H), 1.38 (m, 6H) ppm; 13C NMR (75 MHZ, 
CDCl3) 6 142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm. 
30 
35 
40 
Example 5 
Preparation of 5',5",5"'-(1,2,4,5-benZentetrayl)-tet 
rakis(1-bromopentane) 45 
HO OH 
_, 50 
HO OH 
Br Br 
Br Br 
55 
Br % 
Br % 
20 
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis-pentan-1-ol 
(1.97 g, 4.67 mmol) and carbon tetrabromide (7.22 g, 
21.74.80 mmol) Were dissolved in dry methylene chloride (50 
mL) and cooled to 0° C. Triphenyl phosphine (5.70 g, 22.02 
mmol) Was added portion-Wise and the mixture Was stirred at 
RT. After the starting alcohol Was consumed methanol Was 
added and the mixture Was stirred for an additional 5 minutes. 
The mixture concentrated and Was treated With hexanes (500 
mL) and then ?ltered through a short silica gel column, and 
Washed With ethylacetate/hexanes (1/4). The combined 
organic solvents Were evaporated to dryness under reduced 
pressure. The resulting residue Was puri?ed by column chro 
matography (hexanes) to afford 2.83 g of the title compound. 
Yield: 90%. 1H NMR (300 MHZ, CDCl3) 6 6.89 (s, 2H), 3.42 
(t, J:7.2 HZ, 8H), 2.55 (m, 8H), 1.90 (m, 8H), 1.45-1.62 (m, 
16H) ppm. 
Example 6 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetraki s [4-pentyn-1 -yl- (3 -methylpyridinium)]tetra 
bromide 
Br % % Br 
Br % % Br 
6 9 
/ \6 Br Br 6 _ 
_ N % 4 N\ / 
/ \3 % § ‘§\ / 
— Bre B? 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-pentyne (300 mg, 0.46 mmol) and 3-picoline (607 
mg, 6.52 mmol) Was heated at 60-700 C. for 12 hrs. The 
resulted mixture Was treated With diethyl ether and then dis 
solved in Water (15 mL), the aqueous solution Was extracted 
extensively With chloroform (30 mL><5). Water Was removed 
by lyophiliZation to afford 385 mg of the title compound. 
Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 9.01 9.11 (s, 
4H), 9.01 (d, 1:6 HZ, 4H), 8.38 (d, J:8.1 HZ, 4H), 8.01 (t, 
11:6 HZ, 12:81 HZ, 4H), 7.41 (s, 2H), 4.88 (t, 1:84 HZ, 8H), 
2.74 (t, 1:66 HZ, 8H), 2.57 (s, 12H), 2.40 (p, 1:66 HZ, 8H) 
PPm~ 
Example 7 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[4-pentyn-1 -yl-(4 -methylpyridinium)]tetra 
rom1de 
% Br 
% Br 
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-continued 
B 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-penyne (300 mg, 0.46 mmol) and 4-picoline (600 
mg, 6.50 mmol) Was heated at 60-700 C. for 12 hrs. The 
resulted mixture Was treated With diethyl ether and then dis 
solved in Water (15 mL), the aqueous solution Was extracted 
extensively With chloroform (30 mL><5). Water Was removed 
by lyophiliZation to afford 408 mg of the title compound. 
Yield: 87%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.95 (d, 
1:60 HZ, 8H), 7.92 (d, 1:60 HZ, 8H), 7.37 (s, 2H), 4.82 (t, 
1:63 HZ, 8H), 2.71 (t, 1:66 HZ, 8H), 2.58 (s, 12H), 2.35 (p, 
1:66 HZ, 8H) ppm. 
Example 8 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetraki s [4-pentyn-1 -yl- (3 ,4 -dimethylpyridinium)] 
tetrabromide 
Br % % Br 
Br % % Br 
6 
/ \@ Br 
N § % 
/ \1? ¢ % 
— Bre 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-pentyne (300 mg, 0.46 mmol) and 3,4-lutidine (650 
mg, 5.0 mmol) Was heated at 60-700 C. for 12 hrs. The 
resulted mixture Was treated With diethyl ether and then dis 
solved in Water (15 mL), the aqueous solution Was extracted 
extensively With chloroform (30 mL><5). Water Was removed 
by lyophiliZation to afford 374 mg of the title compound. 
Yield: 75%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.91 (s, 
4H), 8.80 (d, 1:60 HZ, 4H), 7.85 (d, 1:66 HZ, 4H), 7.32 (s, 
2H), 4.78 (t, 1:66 HZ, 8H), 2.71 (t, 1:63 HZ, 8H), 2.46 (s, 
12H), 2.43 (s, 12H), 2.35 (t, 1:66 HZ, 8H) ppm. 
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Example 9 
Preparation of 5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl) 
tetraki s [4-pentyn-1 -yl- (3 ,5 -dimethylpyridinium)] 
tetrabromide 
// 
-continued 
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1- 8H), 8.17 (s, 4H), 7.39 (s, 4H), 4.79 (t, J:7.1 HZ, 8H), 2.72 (t, 
bromo-4-pentyne (300 mg, 0.46 mmol) and 3,5-lutidine (650 1:66 HZ, 8H), 2.51 (s, 24H), 2.37 (t, 1:66 HZ, 8H) ppm. 
mg, 5.0 mmol) Was heated at 60-700 C. for 12 hrs. The 
resulted mixture Was treated With diethyl ether and then dis 
solved in Water (15 mL), the aqueous solution Was extracted 5 Example 10 
extensively With chloroform (30 mL><5). Water Was removed 
by lyophiliZation to afford 425 mg of the title compound. Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
Yield: 85%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.86 (s, tetrakis(4-pentyn-1-yl-nicotinium)tetrabromide 
Br % % Br 
—> 
Br % % Br 
N/ \N 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-pentyne (300 mg, 0.46 mmol) and S(—)-nicotine 
(320 mg, 2 mmol) in acetonitrile Was heated at 60-700 C. for 
24 hrs. The resulted mixture Was treated With diethyl ether 
and then dissolved in Water (1 5 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 
removed by lyophiliZation to afford 390 mg of the title com 
45 pound. Yield: 60%. 1H NMR (300 MHZ, CD3OD) 6 99.15 (s, 
4H), 9.05 (d, 1:6 HZ, 4H), 8.54 (d, J:7.8 HZ, 4H), 8.10 (t, 
11:6 HZ, J2:7.8 HZ, 4H), 7.48 (s, 2H), 4.91 (t, J:7.5 HZ, 8H), 
3.55 (t, J:8.1 HZ, 4H), 3.24 (m, 4H), 2.71 (t, J:8.1 HZ, 8H), 
2.36-2.47 (m, 16H), 2.25 (s, 12H), 1.89-1.95 (m, 8H), 1.72 
50 1.76 (m, 4H) ppm. 
40 
Example 1 1 1 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[4-pentyn-1 -yl-(5, 6,7, 8-tetrahydroisoquino 
linium)]tetrabromide 
Br % % Br 
Br % % Br 
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-continued 
Br B9 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1- 15 (br, 16H). 13C NMR, 159.92, 145.40, 141.74,140.03, 136.20, 
bromo-4-pentyne (300 mg, 0.46 mmol) and 5,6,7,8-tetrahy- 129.26, 126.28, 95.18, 80.49, 61.50, 30.94, 30.56, 27.51, 
droisoquinoline (260 mg, 2.0 mmol) Was heated at 60-700 C. 22-30, 22-19, 1773 ppm 
for 1 8 hrs. The resulted mixture Was treated With diethyl ether 
and then dissolved in Water (15 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 20 Exampk; 12 
removed by lyophiliZation to afford 320 mg of the title com 
pound.Yield: 80%. 1H NMR (300 MHZ) 6 (CD3Cl), 8.86 (s, Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
4H), 8.72 (d, 4H), 7.75 (s, 4H), 7.30 (s, 2H), 4.74 (t, J:8.1 HZ, tetrakis[4-pentyn-1-yl-(3-phenyl-pyridinium)]tetra 
8H), 2.91 (br, 16H), 2.72 (t, 1:66 HZ, 8H), 2.35 (m, 8H), 1.80 bromide 
Br % % Br 
Br % § Br 
9 
Br Br _ 
/ \o o 
N N 
_ § % \ / 
<+> @ — 
/ \ f % N 
_ e \ / 
Br Br6 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
55 bromo-4-pentyne (300 mg, 0.46 mmol) and 3-phenylpyridine 
(310 mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs. The 
resulting mixture Was treated With diethyl ether and then 
dissolved in Water (15 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 
60 removed by lyophiliZation to afford 440 mg of the title com 
pound. Yield: 75%. 1H NMR (300 MHZ, CD3OD) 6 ppm 9.50 
(s, 4H), 9.09 (d, 1:60 HZ, 4H), 8.73-8.76 (m, 4H), 7.12-7.16 
(m, 4H), 7.76-7.81 (m, 8H), 7.52-7.57 (m, 12H), 7.23 (s, 2H), 
4.95 (t, J:8.4 HZ, 8H), 2.71 (t, 1:66 HZ, 8H), 2.40 (m, 8H) 
65 ppm. 13C NMR, 144.23, 142.61, 136.23, 134.47, 131.51, 
130.78, 139.56, 128.70, 126.13, 94.82, 80.97, 62.58, 31.08, 
17.68 ppm. 
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Example 13 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[4-pentyne-1-yl-(isoquinolinolinium)]tetra 
bromide 
Br Br % 
28 
A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-pentyne (300 mg, 0.46 mmol) and isoquinoline (260 
mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs. The 
resulting mixture Was treated With diethyl ether and then 
dissolved in Water (15 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 
removed by lyophiliZation to afford 442 mg of the title com 
pound.Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 10.14 (s, 
4H), 8.80 (d, 1:66 HZ, 4H), 8.47 (d, 1:75 HZ, *H), 8.147 
8.17 (m, 8H), 8.00 (m, 4H), 6.59 (s, 2H), 5.02 (t, 1:66 HZ, 
8H), 2.79 (t, 1:63 HZ, 8H), 2.44-2.50 (m, 8H) ppm. l3C 
Br % 
Br 
% 
% 
NMR, 144.23, 142.61, 136.23, 134.48, 131.51, 130.78, 
129.56, 128.70, 126.13, 94.82, 80.97, 62.57, 31.08, 17.68 
Example 14 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis [4 -pentyn- 1 -yl- (3 -benZyl-pyridinium)]tetra 
bromide 
Br 
Br 
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1 
bromo-4-pentyne (300 mg, 0.46 mmol) and 3-benZyl pyri 
dine (340 mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs. 
The resulting mixture Was treated With diethyl ether and then 
dissolved in Water (15 mL), the aqueous solution Was 5 
extracted extensively With chloroform (30 mL><5). Water Was 
removed by lyophiliZation to afford 521 mg of the title com 
pound. Yield: 85%. 1H NMR (300 MHZ, CD3OD) 6 9.21 (s, 
4H), 9.02 (d, 4H), 8.26 (d, 4H), 8.00 (dd, 4H), 7.42 (s, 2H), 
7.18-7.28 (m, 20H), 4.86 (t, 8H), 4.22 (s, 8H), 2.67 (t, 8H), 
2.34-2.44 (m, 8H) ppm. 
Example 15 
Preparation of 5, 5',5 ", 5"'-(1 ,2,4, 5-benZentetrayl) 
tetrakis {4-pentyn-1 -yl-[3-(3 -hydroxypropyl) -pyri 
dinium] }tetrabromide 
Br % % Br 
Br % % Br 
HO 
9 
/ \@ Br 
N % ¢ 
/ \i % % 
HO — BIG 
A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
bromo-4-pentyne] (300 mg, 0.46 mmol) and 3-hydroxypro 
pylpyridine (340 mg, 2.0 mmol) Was heated at 60-700 C. for 
18 hrs. The resulting mixture Was treated With diethyl ether 
and then dissolved in Water (15 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 
removed by lyophiliZation to afford 350 mg of the title com 
pound. Yield: 63%. 1H NMR (300 MHZ, CD3OD) 6 9.14 (s, 
4H), 9.04 (d, 1:60 HZ, 4H), 8.45 (d, J:8.1 HZ, 4H), 8.05 (dd, 
11:60 HZ, 12:81 HZ, 4H), 7.39 (s, 2H), 4.90 (t, 1:69 HZ, 
8H), 3.61 (t, 1:60 HZ, 8H), 2.96 (t, J:7.8 HZ, 8H), 2.75 (t, 
1:66 HZ, 8H), 2.36-2.45 (m, 8H), 1.88-1.97 (m, 8H) ppm. 
45 
50 
Example 16 55 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[pentanyl-(3 -methyl-pyridinium)]tetrabro 
mide 
Br Br 
Br Br 
60 
30 
-continued 
9 9 _ 
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A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
bromopentane] (330 mg, 0.49 mmol) and 3-picoline (220 mg, 
2.3 mmol) Was heated at 60-700 C. for 18 hrs. The resulting 
H Bre _ O 
N 
N 
B9 OH 
mixture Was treated With diethyl ether and then dissolved in 
Water (15 mL), the aqueous solution Was extracted exten 
sively With chloroform (30 mL><5). Water Was removed 
through lyophiliZation to afford 400 mg of the title com 
pound. Yield: 78%. 1H NMR (300 MHZ, CD3OD) 6 ppm 9.08 
(s, 4H), 8.96 (d, 1:60 HZ, 4H), 8.47 (d, J:8.1 HZ, 4H), 8.02 
(dd, J1:8.1 HZ, 12:60 HZ, 4H). 6.92 (s, 2H), 4.70 (t, J:7.8 
HZ, 8H), 2.61 (s, 12H), 2.58 (t, J:7.8 HZ, 8H), 2.08-2.14 (m, 
8H), 1.50-1.65 (m, 8H), 1.45-1.52 (m, 8H) ppm. 13C NMR, 
146.10, 144.43, 141.97, 139.95, 137.35, 130.17, 127.60, 
61.71, 32.07, 31.54, 31.09, 26.24, 17.79 ppm. 
Example 17 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[pentanyl-(4 -methyl-pyridinium)]tetrabro 
mide 
Br Br 
Br Br 
US 8,629,163 B2 
31 
-continued 
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Amixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
bromopentane] (330 mg, 0.49 mmol) and 4-picoline (220 mg, 
2.3 mmol) Was heated at 60-700 C. for 18 hrs. The resulting 
mixture Was treated With diethyl ether and then dissolved in 
Water (15 mL), the aqueous solution Was extracted exten 
sively With chloroform (30 mL><5). Water Was removed 
through lyophiliZation to afford 425 mg of the title com 
pound. Yield: 83%. 1H NMR (300 MHZ, CD3OD) 6 8.97 (d, 
1:66 HZ, 8H), 7.97 (d, 1:66 HZ, 8H), 6.91 (s, 2H), 4.67 (t, 
1:75 HZ, 8H), 2.67 (s, 12 HZ), 2.57 (t, 1:75 HZ, 8H), 2.04 
2.11 (m, 8H), 1.57-1.65 (m, 8H), 1.46-1.50 (m, 8H) ppm. 13C 
NMR, 159.69, 143.48, 137.35, 130.17, 128.79, 61.01, 32.05, 
31.42, 31.09, 26.17 ppm. 
Example 18 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[pentanyl-(3,4-dimethyl-pyridinium)]tetra 
bromide 
—> 
Br Br 
G) 9 _ 
N N 
_ BIG 9 \ / 
Br 
Amixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
bromopentane] (330 mg, 0.49 mmol) and 3,4-lutidine (220 
mg, 2.3 mmol) Was heated at 60-700 C. for 18 hrs. The 
resulting mixture Was treated With diethyl ether and then 
dissolved in Water (15 mL), the aqueous solution Was 
Br 
Br 
20 
30 
40 
45 
50 
55 
32 
extracted extensively With chloroform (30 mL><5). Water Was 
removed through lyophiliZation to afford 421 mg of the title 
compound.Yield: 78%. 1H NMR (300 MHZ, CD3OD) 6 8.84 
(s, 4H), 8.73 (d, 1:63 HZ, 4H), 7.86 (d, 1:63 HZ, 4H0, 6.89 
(s, 2H), 4.57 (t, 1:75 HZ, 8H), 2.58 s, 12 H), 2.56 (t, 1:75 HZ, 
8H), 2.48 (s, 12 H), 2.01-2.08 (m, 8H), 1.56-1.64 (m, 8H), 
1.42-1.49 (m, 8H) ppm. 13C NMR, 158.40, 142.97, 141.35, 
138.69, 137.28, 130.11, 128.27, 60.85, 32.04, 31.41, 31.08, 
26.22, 15.94 ppm. 
Example 19 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[pentanyl-(3 ,5 -dimethyl-pyridinium)]tetra 
bromide 
Br Br 
Br Br 
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A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
bromopentane] (330 mg, 0.49 mmol) and 3,5-lutidine (220 
mg, 2.3 mmol) Was heated at 60-700 C. for 18 hrs. The 
resulting mixture Was treated With diethyl ether and then 
dissolved in Water (15 mL), the aqueous solution Was 
extracted extensively With chloroform (30 mL><5). Water Was 
removed through lyophiliZation to afford 475 mg of the title 
compound.Yield: 88%. 1H NMR (300 MHZ, CD3OD) 6 8.76 
(s, 8H), 8.25 (s, 6.90 (s, 2H), 4.57 (t, J:7.8 HZ, 8H), 2.57 (t, 
1:75 HZ, 2.53 (s, 12H), 2.03-2.08 (m, 8H), 2.58-1.64 (m, 
8H), 1.45-1.50 (m, 8H) ppm. 13C NMR, 147.72, 142.75, 
140.37, 138.52, 131.34, 62.77, 33.27, 32.73, 32.34, 27.53, 
18.55 ppm. 
Example 20 
Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
tetrakis[pentanyl-(nicotinium)]tetrabromide 
Br 
Br 
US 8,629,163 B2 
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Amixtureof5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1- (m, 16 HZ), 1.74-1.78 (m, 4H), 1.61 (br, 8H), 1.48 (br, 8H) 
bromopentane] (330mg, 04911111101) andS-(-)-njcotine (355 ppm. 13C NMR, 145.80, 144.43, 143.72, 143.44, 137.28, 
mg, 23 mmol) Was heated at 60-700 C_ for 18 hrs The 25 128.12, 67.45, 61.89, 56.79, 39.69, 35.14, 32.05, 31.55, 
resulted mixture Was treated With diethyl ether and then dis- 31'06’ 26'25’ 2293 Ppm' 
solved in Water (15 mL), the aqueous solution Was extracted 
extensively With chloroform (30 mL><5). Water Was removed 
through lyophiliZation to afford 362 mg of the title com- Example 21 
pound. Yield: 56%. 1H NMR (300 MHZ, CD3OD) 6 9.06 (s, 30 
4H), 8.96 (d, 1:66 HZ, 4H), 8.57 (d, J:8.1 HZ, 4H), 8.07 (dd, Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl) 
4H), 6.89 (s, 2H), 4.69 (t, 117.5 HZ, 8H), 3.54 (m, 4H), tetrakis[pentanyl-(3-(3-hydroxypropanyl)pyri 
3.24-3.34 (m, 4H), 2.38-2.59 (8H), 2.24 (s, 12H), 1.90-2.11 dinium)]tetrabromide 
Br Br 
Br Br 
6 HO Br 
(9 / \N 6 OH 
— Br (9 \ 
N\ 
/ \ o o — 
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A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1 
55 bromopentane] (330 mg, 0.49 mmol) and 3-(3-hydroxypro 
panyl)-pyridine (325 mg, 2.3 mmol) Was heated at 60-700 C. 
for 18 hrs. The resulting mixture Was treated With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
tion Was extracted extensively With chloroform (30 mL><5). 
Water Was removed through lyophiliZation to afford 371 mg 
60 of the title compound. Yield: 62%. 1H NMR (300 MHZ, 
CD3OD) 6 9.07 (s, 4H), 8.94 (d, 1:60 HZ, 4H), 8.50 (d, J:8.4 
HZ, 4H), 8.05 (dd, 4H), 6.90 (s, 2H), 4.69 (t, J:7.5 HZ, 8H), 
3.62 (t, 1:60 HZ, 8H), 2.99 (t, 7.8 HZ, 8H), 2.57 (t, J:7.5 HZ, 
8H), 2.05-2.12 (m, 8H), 1.93-1.98 (m, 8H), 1.57-1.62 (m, 
65 8H), 1.46-1.50 (m, 8H) ppm. 13C NMR, 145.53, 144.24, 
143.98, 142.24, 137.30, 130.15, 127.80, 61.77, 60.48, 33.08, 
32.05, 31.55, 31.06, 29.12, 26.20 ppm. 














